Earlier this week, a government investigation revealed that China’s Changchun Changsheng bio-technology corporation had sold over 250,000 substandard DPT vaccines that were administered to inoculate infants as young as three months old against diphtheria, whooping cough and tetanus.

The investigation also discovered that the company had forged data pertaining to the production of over 100,000 rabies vaccines. The latest in a litany of food and drug safety scares, the Changsheng case has sparked both intense criticism of the Chinese government’s ability to regulate the space at home, and concerns about China’s recent push to market pharmaceuticals abroad. Indeed, implications extend well beyond the immediate fallout of the scandal

Author

Leave a Reply

Your email address will not be published. Required fields are marked *